[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-study-detail:100632269":3},{"organization":4,"armGroups":7,"interventions":24,"overallOfficials":23,"centralContacts":32,"locations":38,"responsibleParty":56,"collaborators":23,"id":59,"slug":23,"hasResults":60,"nctId":61,"briefTitle":62,"officialTitle":63,"acronym":23,"eligibilityCriteria":64,"healthyVolunteers":60,"sex":65,"minAge":66,"maxAge":67,"enrollmentInfo":68,"targetDuration":23,"studyType":71,"phases":72,"briefSummary":74,"conditions":75,"keywords":23,"overallStatus":40,"whyStopped":23,"lastUpdateSubmitDate":82,"lastUpdatePostDateStruct":83,"startDateStruct":86,"completionDateStruct":88,"leadSponsor":90,"locationsCount":91},{"fullName":5,"class":6},"Tanta University","OTHER",[8,14,19],{"label":9,"type":10,"description":11,"interventionNames":12},"Group L","EXPERIMENTAL","Patients will receive ondansetron lozenge 4 mg (Ondalenz ©), 2 hours before surgery.",[13],"Drug: Ondansetron lozenge",{"label":15,"type":10,"description":16,"interventionNames":17},"Group O","Patients will receive 8 mg of ondansetron IV just before the surgery.",[18],"Drug: Ondansetron intravenous",{"label":20,"type":21,"description":22,"interventionNames":23},"Group C","NO_INTERVENTION","Patients will not receive ondansetron as a control group.",null,[25,29],{"type":26,"name":27,"description":11,"armGroupLabels":28,"otherNames":23},"DRUG","Ondansetron lozenge",[9],{"type":26,"name":30,"description":16,"armGroupLabels":31,"otherNames":23},"Ondansetron intravenous",[15],[33],{"name":34,"role":35,"phone":36,"phoneExt":23,"email":37},"Mohammed S Elsharkawy, MD","CONTACT","00201148207870","mselsharkawy@med.tanta.edu.eg",[39],{"facility":5,"status":40,"city":41,"state":42,"zip":43,"country":44,"cosmosGeoPoint":45,"geoPoint":50,"contacts":51},"RECRUITING","Tanta","El-Gharbia","31527","Egypt",{"type":46,"coordinates":47},"Point",[48,49],31.00192,30.78847,{"lat":49,"lon":48},[52,53],{"name":34,"role":35,"phone":36,"phoneExt":23,"email":37},{"name":54,"role":55,"phone":23,"phoneExt":23,"email":23},"Salma E Kandil, MD","PRINCIPAL_INVESTIGATOR",{"type":55,"investigatorFullName":57,"investigatorTitle":58,"investigatorAffiliation":5,"oldNameTitle":23,"oldOrganization":23},"Mohammed Said ElSharkawy","Lecturer of Anesthesiology, Surgical Intensive Care and Pain Medicine, Faculty of Medicine, Tanta University, Tanta, Egypt","100632269",false,"NCT07511491","Ondansetron Lozenge Versus Intravenous for Prevention of Shivering in Cesarean Section","Effect of Ondansetron Lozenge Versus Intravenous for Prevention of Shivering in Cesarean Section: A Randomized Controlled Trial","Inclusion Criteria:\n\n* Age from 18 to 40 years.\n* American Society of Anesthesiology (ASA) physical status II.\n* Parturient women undergoing cesarean section under spinal anesthesia.\n\nExclusion Criteria:\n\n* Parturient women with any contraindication or hypersensitivity to the study drugs.\n* Any history of cardiovascular diseases, psychosis, hypertension, fetal distress, cord prolapse initial.\n* Preoperative shivering.\n* Preoperative fever (\\>38°C).\n* Body mass index \\> 40 kg\u002Fm2.\n* Medical history of alcohol or drug abuse.\n* Hypo- or hyperthyroidism.\n* Parkinson's disease or any extrapyramidal disease.\n* Intraoperative blood transfusion.","FEMALE","18 Years","40 Years",{"count":69,"type":70},90,"ESTIMATED","INTERVENTIONAL",[73],"NA","This study aims to compare the effect of ondansetron lozenge and intravenous for prevention of shivering in cesarean section (CS).",[76,77,78,79,80,81],"Ondansetron","Lozenge","Intravenous","Prevention","Shivering","Cesarean Section","2026-06-22",{"date":84,"type":85},"2026-06-23","ACTUAL",{"date":87,"type":85},"2026-04-11",{"date":89,"type":70},"2026-08-30",{"name":5,"class":6},1]